Last reviewed 2026-05-14 · How we verify

2024 Pharmaceutical Patent Cliff

29 marketed drugs with patents expiring in 2024, joined to sponsor + therapeutic area + drug class. Historical archive. Sourced from FDA Orange Book + USPTO Patent Public Search.

Sponsors most affected (10)

1. Pfizer · 7 drugs
2. Merck & Co. · 2 drugs
3. Novartis · 2 drugs
4. Foldrx Pharms · 1 drug
5. MYOVANT SCIENCES · 1 drug
6. ANI Pharmaceuticals · 1 drug
7. Unknown · 1 drug
8. ASTRAZENECA LP · 1 drug
9. AstraZeneca · 1 drug
10. UCB · 1 drug

By therapeutic area

Oncology (10)

• 2024-01-25 — Torisel · Pfizer · temsirolimus
• 2024-01-28 — Orgovyx · MYOVANT SCIENCES · Gonadotropin Releasing Hormone Receptor Antagonist [EPC]
• 2024-03-13 — Koselugo · ASTRAZENECA LP · Kinase Inhibitor [EPC]
• 2024-03-13 — Mektovi · Pfizer
• 2024-06-09 — Taxol · Pfizer · Microtubule Inhibitor
• 2024-06-25 — Pepaxto · Oncopeptides Ab · Alkylating Drug
• 2024-08-25 — Viekira Pak (Copackaged) · AbbVie · Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor
• 2024-08-27 — Sandimmune · Novartis · Calcineurin Inhibitor Immunosuppressant [EPC]
• 2024-09-24 — Cometriq · Exelixis · Kinase Inhibitor
• 2024-12-10 — Nogitecan · Novartis · topotecan

Metabolic (7)

• 2024-01-11 — Vantobra · Pfizer · tobramycin
• 2024-01-31 — Zuragard · isopropanol
• 2024-04-15 — Byetta · AstraZeneca · GLP-1 Receptor Agonist [EPC]
• 2024-04-19 — Amphetamine Sulfate · UCB · Central Nervous System Stimulant
• 2024-05-06 — Premarin · Pfizer · Estrogen [EPC]
• 2024-05-23 — Ozempic · Novo Nordisk · GLP-1 Receptor Agonist [EPC]
• 2024-11-18 — Cuvposa · Shionogi · Anticholinergic

Immunology (3)

• 2024-05-21 — Vizamyl · GE HealthCare · Radioactive Diagnostic Agent [EPC]
• 2024-05-25 — Tussionex Pennkinetic · Bayer · Histamine-1 Receptor Antagonist
• 2024-06-01 — Fluvastatin, Tacrolimus, Mycophenolat Mofetil · University Hospital Schleswig-Holstein · ["Statins", "Immunosuppressants", "Immunosuppressants"]

Neuroscience (2)

• 2024-01-28 — Vyndaqel · Foldrx Pharms · tafamidis
• 2024-01-30 — Phenergan Vc W/ Codeine · ANI Pharmaceuticals · Nonsteroidal Anti-inflammatory Drug [EPC]

Bone (2)

• 2024-01-30 — Ortho-Novum 10/11-21 · Merck & Co. · Estrogen
• 2024-05-06 — Duavee · Wyeth Pharms Pfizer · Estrogen [EPC]

Cardiovascular (1)

• 2024-08-26 — Proventil · Merck & Co. · beta2-Adrenergic Agonist

Ophthalmology (1)

• 2024-09-01 — Miralax · Braintree · Osmotic Laxative [EPC]

Other (1)

• 2024-09-01 — Sodium Chloride · Pfizer · sodium chloride

Gastroenterology (1)

• 2024-09-30 — Pantoprazole Sodium · Pfizer · Proton pump inhibitor (PPI)

Respiratory (1)

• 2024-10-08 — Xopenex · Oak Pharms Inc · beta2-Adrenergic Agonist

Subscribe to patent-cliff alerts

Push every new patent expiry into your RSS reader:

• Marketed-drug events RSS
• All 2024 pharma events (approvals + readouts + patents)

Related

• Biosimilar tracker — who's competing for each post-cliff originator
• Patent cliff revenue calculator
• 2024 patent expiries dataset (CSV / JSON)